Abstract
Purpose
Endometrial adenocarcinoma, due to a frequent activation of PI3 K/AKT has been proposed as a candidate neoplasm for the treatment with mTOR inhibitors. Yet, data on the expression of mTOR cascade components in endometrial cancer are lacking.
Methods
To provide a basis for futher studies with mTOR inhibitors, we used immunohistochemistry to evaluate the expression of activated mTOR pathway components in 57 endometrial cancer surgical specimens in vivo, and investigated in vitro the relation between the activation of AKT/mTOR and the response to rapamycin.
Results
p-mTOR expression was associated with nuclear p-4EBP1 expression (P = 0.02), and was more frequent in tumors extending ouside the uterine corpus (P = 0.011). Nuclear p-4EBP1 expression was increased in carcinomas of poor differentiation (P = 0.012). In cultivated PTEN-deficient Ishikawa cells, in addition to an activation of AKT, a phosphorylation of mTOR and 4EBP1 was evident, while PTEN-wild type HEC-1A cells lacked AKT activation but revealed a reduced expression of p-mTOR and p-4EBP1. Rapamycin induced a growth reduction, which was clearly more pronounced in Ishikawa cells than in HEC-1A cells (P < 0.03) and could be observed for up to 6 days.
Conclusisons
Expression of mTOR and 4EBP1 characterize high-grade, high-stage endometrial adenocarcinomas and might be predictive markers of a response to rapamycin. Based on our results, we suggest that the expression of elements of the mTOR pathway in human tumor tissue should be further evaluated as a possible predictive marker in large-scale clinical studies as well as translational research protocols in clinical studies with mTOR inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armengol G, Rojo F, Castellvi J et al (2007) 4E-binding protein 1: a key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 67:7551–7555. doi:10.1158/0008-5472.CAN-07-0881
Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF (2006) Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol Oncol 100:487–494. doi:10.1016/j.ygyno.2005.08.053
Bayascas JR, Alessi DR (2005) Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 18:143–145. doi:10.1016/j.molcel.2005.03.020
Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801–1811. doi:10.1002/cncr.22195
Chow LM, Baker SJ (2006) PTEN function in normal and neoplastic growth. Cancer Lett 241:184–196. doi:10.1016/j.canlet.2005.11.042
Culjkovic B, Topisirovic I, Borden KL (2007) Controlling gene expression through RNA regulons: the role of the eukaryotic translation initiation factor eIF4E. Cell Cycle 6:65–69
Dudkin L, Dilling MB, Cheshire PJ et al (2001) Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 7:1758–1764
Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25:6436–6446. doi:10.1038/sj.onc.1209886
Gadducci A, Cosio S, Genazzani AR (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58:242–256. doi:10.1016/j.critrevonc.2005.11.002
Gao N, Flynn DC, Zhang Z et al (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3 K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287:C281–C291. doi:10.1152/ajpcell.00422.2003
Hecht JL, Mutter GL (2006) Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 24:4783–4791. doi:10.1200/JCO.2006.06.7173
Herberger B, Puhalla H, Lehnert M et al (2007) Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma. Clin Cancer Res 13:4795–4799. doi:10.1158/1078-0432.CCR-07-0738
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66
Kanamori Y, Kigawa J, Itamochi H et al (2001) Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 7:892–895
Kremer CL, Klein RR, Mendelson J et al (2006) Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66:1203–1212. doi:10.1002/pros.20410
Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR (1999) Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344:427–431. doi:10.1042/0264-6021:3440427
Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669–10673. doi:10.1158/0008-5472.CAN-05-2620
Pectasides D, Pectasides E, Economopoulos T (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33:177–190. doi:10.1016/j.ctrv.2006.10.007
Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649–662. doi:10.1016/j.humpath.2004.02.007
Rojo F, Najera L, Lirola J et al (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13:81–89. doi:10.1158/1078-0432.CCR-06-1560
Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16:564–575. doi:10.1097/01.cco.0000143964.74936.d1
Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6:729–734. doi:10.1038/nrc1974
Steiner E, Eicher O, Sagemuller J et al (2003) Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 13:197–203. doi:10.1046/j.1525-1438.2003.13021.x
Tavassoli FA, Devilee P (2003) World Health Organization classification of tumours: tumours of the breast and the female genital organs. IARC Press, Lyon
Treeck O, Wackwitz B, Haus U, Ortmann O (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol Oncol 102:292–299. doi:10.1016/j.ygyno.2005.12.019
Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484. doi:10.1016/j.cell.2006.01.016
Zhou C, Gehrig PA, Whang YE, Boggess JF (2003) Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2:789–795
Zhou X, Tan M, Stone Hawthorne V et al (2004) Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10:6779–6788. doi:10.1158/1078-0432.CCR-04-0112
Acknowledgments
We would like to thank Mrs. Ines Koch and Mrs. Petra Wachs for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors Silvia Darb-Esfahani and Areeg Faggad contributed equally to the publication.
Rights and permissions
About this article
Cite this article
Darb-Esfahani, S., Faggad, A., Noske, A. et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135, 933–941 (2009). https://doi.org/10.1007/s00432-008-0529-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0529-5